$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

2024-04-18

2025-03-10

2025-03-10

13

Study Overview

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

The primary objectives of Part 1 of this study are to: * Assess the safety and tolerability of the combination of BGB-3245 and panitumumab in participants with advanced or metastatic colorectal cancer (CRC) with a known mutation status and tumor harboring an oncogenic mutation of v-Raf murine sarcoma viral oncogene homolog B; B-RAF proto-oncogene, serine/threonine kinase (BRAF), Kirsten rat sarcoma viral oncogene homolog (KRAS), or neuroblastoma RAS viral oncogene homolog (NRAS) with documented disease progression during or after at least 1 line of prior therapy. * Determine the maximum tolerated dose (MTD) of BGB-3245 in combination with panitumumab and the recommended phase 2 dose (RP2D) of the combination. The primary objective of Part 2 of this study is to determine the objective response rate (ORR) as assessed by initial investigator review using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 with BGB-3245 and panitumumab combination treatment at the RP2D.

N/A

  • Colorectal Cancer
  • Pancreatic Ductal Cancer
  • Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
  • DRUG: BGB-3245
  • DRUG: Panitumumab
  • BGB-3245-EGFR-001

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2023-12-22  

N/A  

2025-04-16  

2023-12-22  

N/A  

2025-04-20  

2024-01-08  

N/A  

2025-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Part 1: Dose Finding Part

Participants with advanced or metastatic CRC and with known mutation status and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS and with documented disease progression by RECIST during or after at least 1 line of prior therapy will be enrolle

DRUG: BGB-3245

  • Oral capsule

DRUG: Panitumumab

  • Intravenous (IV) infusion via an infusion pump
EXPERIMENTAL: Part 2: Dose Expansion Part, Group 1

Participants with advanced or metastatic CRC that harbors KRAS or NRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-32

DRUG: BGB-3245

  • Oral capsule

DRUG: Panitumumab

  • Intravenous (IV) infusion via an infusion pump
EXPERIMENTAL: Part 2: Dose Expansion Part, Group 2

Participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that harbors KRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants wil

DRUG: BGB-3245

  • Oral capsule

DRUG: Panitumumab

  • Intravenous (IV) infusion via an infusion pump
Primary Outcome MeasuresMeasure DescriptionTime Frame
Part 1: Number of Participants with Serious Adverse Events (SAEs)Up to approximately 2 years
Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Up to approximately 2 years
Part 1: Number of Participants with Adverse Events of Special Interest (AESIs)Up to approximately 2 years
Part 1: Number of Participants with Interruptions to Dosing with BGB-3245Up to approximately 2 years
Part 1: Number of Participants with Reductions in Dosing with BGB-3245Up to approximately 2 years
Part 1: MTD of BGB-3245Up to approximately 2 years
Part 1: RP2D of BGB-3245Up to approximately 2 years
Part 2: ORR as Assessed by Initial Investigator ReviewUp to approximately 2 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Part 1 and 2: Plasma Concentrations of BGB-3245 and Any Relevant MetabolitesDay 1 of each 28 day cycle (up to approximately 2 years)
Part 1: ORR as Assessed by Investigator Review using RECIST v1.1Up to approximately 2 years
Part 2: ORR as Assessed by Central ReviewUp to approximately 2 years
Part 1 and 2: Duration of Response (DoR)Up to approximately 2 years
Part 1 and 2: Disease Control Rate (DCR)Up to approximately 2 years
Part 1 and 2: Progression Free Survival (PFS)Up to approximately 2 years
Part 2: Number of Participants with SAEsUp to approximately 2 years
Part 2: Number of Participants with TEAEsUp to approximately 2 years
Part 2: Number of Participants with AESIsUp to approximately 2 years
Part 2: Number of Participants with Interruptions to Dosing with BGB-3245Up to approximately 2 years
Part 2: Number of Participants with Reductions in Dosing with BGB-3245Up to approximately 2 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Key Inclusion Criteria:
    1. Participants with histologically confirmed advanced or metastatic solid tumors who have had documented disease progression by RECIST criteria during or after at least 1 prior line of systemic anticancer therapies in the representative population or are unable to receive standard of care therapy(ies) as noted by local guidelines. 2. Part 1 (Dose Finding): Participants with CRC with a known mutation status by local testing and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS in the archival tumor sample or fresh tumor biopsy. 3. Part 2 (Dose Expansion): Participants must have a known mutation status by local testing and meet one of the following criteria according to the group they are enrolled into: Group 1: Participants with CRC that harbors KRAS or NRAS mutations in the archival tumor sample or fresh tumor biopsy. Group 2: Participants with PDAC that harbors KRAS mutations in the archival tumor sample or fresh tumor biopsy. 4. Participants must provide archival tumor tissue or a fresh tumor biopsy for retrospective mutation status analysis. 5. Participants must have radiologically measurable disease as defined per RECIST v1.1 at screening. 6. Eastern Cooperative Oncology Group performance status of ≤1 at screening. 7. Adequate hematologic and organ function, as indicated by defined laboratory values, prior to Cycle 1 Day 1. 8. Adequate cardiac function.
    Key Exclusion Criteria:
    1. Participants receiving cancer therapy (chemotherapy or other systemic anticancer therapies, immunotherapy, radiation therapy, or surgery) at the time of Cycle 1 Day 1. 2. Active infection requiring systemic treatment at the start of the study treatment. 3. Clinically significant cardiovascular disease and / or events within 6 months of signing the informed consent form. 4. Participants with toxicities that have not recovered to Grade ≤1 or stabilized and those Grade 2 toxicities listed as permitted in other eligibility criteria. 5. Participants with a history of pneumonitis or interstitial lung disease. 6. Participants with immune-related toxicities that have not resolved with appropriate management. 7. History or presence of gastrointestinal disease or other condition known to interfere with the absorption of drugs. 8. History of ulcerative colitis or Crohn's disease or protracted and ongoing immune-mediated diarrhea from prior checkpoint inhibitor use. 9. History of corneal perforation, keratitis, or severe dry eye. 10. Current evidence of symptomatic central nervous system metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression. 11. Any active malignancy ≤3 years before Cycle 1 Day 1 except for the specific cancer under investigation in this study and any localized or noninvasive cancer that has been treated curatively. 12. Known hypersensitivity to rapidly accelerated fibrosarcoma (RAF) inhibitors, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or their excipients. 13. Any known history of Grade ≥3 toxicity lasting >14 days from another RAF, mitogen activated protein kinase, extracellular signal-regulated kinase, or anti-EGFR antibody inhibitor requiring discontinuation of treatment from these drugs. 14. Receiving any treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor or inducer ≤14 days (or 5 half-lives, whichever is longer) before Cycle 1 Day 1 and until completion of dosing with BGB-3245 for at least 5 half-lives.
    NOTE: Other protocol defined Inclusion/Exclusion criteria apply. Summary of key criteria provided.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate